ETX101
Sponsors
Encoded Therapeutics
Conditions
Dravet Syndrome
Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RecruitingNCT05419492
Start: 2024-05-14End: 2033-01-01Target: 47Updated: 2026-08-21
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
Active, not recruitingNCT06112275
Start: 2024-02-28End: 2030-09-30Updated: 2025-11-14
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
Active, not recruitingNCT06283212
Start: 2024-05-09End: 2030-10-01Updated: 2026-06-08